Neurotrope, Inc. (NASDAQ: NTRP) was established in 2012 and is headquartered in New York City, New York, USA, with 9 full-time employees. It is a biopharmaceutical company focusing on the development of a product platform for the treatment of Alzheimer’s disease (AD).
Neurotrope, Inc. (NTRP):
Neurotrope is a clinical-stage biotechnology company that uses Bryostatin-1 (bryostatin-1) and its analogs to discover and develop targeted therapies for neurodegenerative diseases and developmental disorders. The company’s experience and enthusiasm for new drug therapies has allowed it to develop a pipeline that includes various treatments for serious and difficult-to-treat diseases such as Alzheimer’s disease, Fragile X syndrome and Niemann-Pick C .
Neurotrope targets Bryostatin-1 due to its high potential and multimodal efficacy: activated by protein kinase C (PKCε), Bryostatin-1 stimulates synaptic growth factor, amyloid-β degrading enzymes, and prevents Tau from transforming into neurofibrils Tangled.
Research has shown that PKCε plays a key role in learning and memory. Bryostatin is a small molecule that can penetrate the blood-brain barrier and activate PKCε, thereby improving synaptic function, forming new synapses, repairing damaged synapses, and preventing neuronal death. Neurotrope’s preclinical work has proved the memory and learning ability of a variety of Alzheimer’s disease mouse models and several other animal models.
Neurotrope’s main product candidate is Bryostatin, a natural product isolated from marine invertebrates, and a bryozoan called Bugula neritina. The company has also developed Bryostatin for other neurodegenerative diseases or cognitive diseases and dysfunctions, such as Fragile X and Niemann-Pick C.
Neurotrope has signed a license agreement with the board of directors of Leland Stanford Junior University to use structural derivatives of Bryostatin (called bryologs) for the treatment of central nervous system diseases, lysosomal storage diseases, stroke, cardioprotection and traumatic brain injury; and acceleration License agreement for the synthesis of Bryostatin-1.
Neurotrope, Inc. has also reached a cooperative research and development agreement with the National Cancer Institute on the research and clinical development of Bryostatin-1.